Although DAT-SPECT imaging has been suggested as an enrichment biomarker to be used in early PD neuroprotection trials, it should be noted that some patients with normal DAT binding but motor scores worsening over the years are at risk to be excluded. Here, SLC6A3 is linked to Parkinson disease.